Dx & Vx Co., Ltd. (KOSDAQ:180400)

Market Cap	453.76B +427.1%
Revenue (ttm)	29.47B -14.7%
Net Income	-50.92B
EPS	-1,033.89
Shares Out	98.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	297,146
Average Volume	541,457
Open	4,820.00
Previous Close	4,820.00
Day's Range	4,550.00 - 4,870.00
52-Week Range	1,319.00 - 5,280.00
Beta	0.29
RSI	59.25
Earnings Date	Nov 14, 2025

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 180400

Financial Performance

In 2024, Dx & Vx's revenue was 33.95 billion, a decrease of -17.69% compared to the previous year's 41.24 billion. Losses were -47.03 billion, 71.1% more than in 2023.